EDISON, N.J., Aug. 11 /PRNewswire-FirstCall/ -- PHARMACEUTICAL FORMULATIONS, INC. (BULLETIN BOARD: PHFR) ("PFI" or the "Company") -- Pharmaceutical Formulations, Inc. is pleased to announce the appointment of Brian Bradley to the new position of Executive Vice President of Sales & Marketing for PFI effective August 2, 2004. Mr. Bradley will be responsible for the entire PFI sales & marketing area and will be part of the PFI executive management team.
Michael A. Zeher, PFI's President & COO, stated, "Brian brings over 20 years of sales and marketing management experience. His background spans the National Brand, Private Label, Value Brand and Exclusive Brands segments. His profound understanding of the challenges and opportunities within the OTC markets will be of immediate value to PFI in helping us to realize our objectives and strategic goals. Also, his strong relationships in the trade should significantly improve PFI's position with major customers."
Most recently Mr. Bradley was President and CEO of USA Labs, an upscale manufacturer of personal care and household consumer products. From 1995 to 2003, he advanced from Vice President of Sales to President and Chief Customer Officer at Lander Co., Inc., a premier custom health & beauty care manufacturing company. Prior to that, he served two years as Sales Director at Schering Plough and eight years in field sales at Wyeth.
Founded in 1964, Pharmaceutical Formulations, Inc. (BULLETIN BOARD: PHFR) , is one of the largest manufacturers of solid dose over the counter consumer pharmaceutical products in the United States and is best known for its private branding and contract manufacturing services. On May 15, 2003 PFI acquired Konsyl Pharmaceuticals Inc., a manufacturer and distributor of powdered natural fiber dietary supplements, which has been in business over 35 years. Products are sold under both the "Konsyl(R)" and SennaPrompt(TM) brand names as well as various private labels. Konsyl also manufactures a gastrointestinal diagnostic product, "Sitzmarks", that is sold to hospitals, colon and rectal surgeons, and radiologists.
ICC Industries Inc. is the holder of approximately 74.5 million shares (about 87%) of the common stock of PFI. ICC is a global leader in the manufacturing, marketing and trading of chemical, plastic and pharmaceutical products. Founded as a trading enterprise in 1952, ICC has grown to include manufacturing, with production facilities in the United States, Europe, the Middle East and Asia.
This press release may contain forward-looking information and should be read in conjunction with the Company's Form 10-K and quarterly and periodic reports on Forms 10-Q and 8-K as filed with the Securities and Exchange Commission.
Pharmaceutical Formulations, Inc.